Supplementary Figure 1. Multi-institution cohort of patients with tumors harboring EGFR Exon 19 deletions. Primary analyses were performed on patients with tumors harboring E746_A750del and L747_A750>P, while investigation into additional uncommon variants was descriptive only. Patient numbers do not reflect the true prevalence of each variant since this cohort is selectively enriched for uncommon exon 19 deletions.

Excluded

- Patients with insufficient data or follow-up
- Patients never treated with osimertinib or received osimertinib<30 days
- Patients treated with osimertinib in later lines without T790M

Patients with \textit{EGFR} exon 19 deletion tumors \(N=341\)

Study Cohort \(N=200\)

Uncommon exon 19 deletions \(N=114\)

- E746_A750del \(N=86\)
- L747_A750>P \(N=36\)
- Other uncommon exon 19 deletions \(n=78\)

L747_P753>S \(N=23\)
L747_T751del \(N=16\)
E746_S752>V \(N=13\)
Others \(N=26\)